Eli Lilly’s Oral GLP-1 Drug Orforglipron Shows Strong Results In Phase III For Type 2 Diabetes

Orforglipron shows major gains in blood sugar and weight loss in Lilly’s Phase 3 diabetes trial.

Simantini Singh Deo | Apr 18, 2025

Atea Pharmaceuticals Appoints Dr. Howard Berman To Board In Agreement With Radoff-JEC Group

Atea adds Dr. Berman to board as observer, advancing HCV program under deal with Radoff-JEC Group.

Simantini Singh Deo | Apr 18, 2025

Africa CDC And WHO Strengthen Mpox Response With Revised Plan Amid Rising Global Cases

Africa CDC & WHO revise mpox plan to expand vaccine access, boost labs, and halt human transmission.

Simantini Singh Deo | Apr 18, 2025

BVI Medical Secures FDA Clearance For Leos™, A Breakthrough In Minimally Invasive Glaucoma Surgery

BVI’s Leos™ gains FDA clearance for minimally invasive glaucoma treatment using laser endoscopy.

Simantini Singh Deo | Apr 18, 2025

Tevogen Bio Secures Strategic Facility Agreement With CD8 To Advance GMP Production And R&D

Tevogen Bio partners with CD8 Tech to launch GMP cell therapy site, boosting in-house R&D capacity.

Simantini Singh Deo | Apr 18, 2025

NewAmsterdam Pharma Appoints Industry Leader Adele Gulfo To Board Of Directors

NewAmsterdam adds Adele Gulfo to Board to guide obicetrapib launch with top-tier pharma expertise.

Simantini Singh Deo | Apr 18, 2025

AI in Pharma

Design Therapeutics Appoints Dr. Chris Storgard as CMO to Drive Clinical Growth

Dr. Chris Storgard joins Design Therapeutics to lead clinical advancement of GeneTAC® therapies.

Mrudula Kulkarni | Apr 18, 2025